NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
0.797
-0.011 (-1.39%)
Jan 22, 2025, 4:00 PM EST - Market closed
NextCure Employees
NextCure had 82 employees as of December 31, 2023. The number of employees decreased by 17 or -17.17% compared to the previous year.
Employees
82
Change (1Y)
-17
Growth (1Y)
-17.17%
Revenue / Employee
n/a
Profits / Employee
-$713,634
Market Cap
22.31M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
NXTC News
- 12 days ago - NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers - GlobeNewsWire
- 6 weeks ago - NextCure Announces Acceptance of IND Application for LNCB74 - GlobeNewsWire
- 2 months ago - NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference - GlobeNewsWire
- 2 months ago - Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta - GlobeNewsWire
- 2 months ago - NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting - GlobeNewsWire
- 3 months ago - NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - GlobeNewsWire
- 4 months ago - NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024 - GlobeNewsWire